Related Experiment Video
Updated: Nov 29, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic Cardiomyopathy in Pregnancy
1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan School of Medicine, 1500 East Medical Center Drive, CVC Suite 2364, Ann Arbor, MI 48109-5853, USA.
Insights
Hypertrophic cardiomyopathy (HCM) in women of childbearing age generally has favorable maternal and fetal outcomes. Genetic counseling and pre-pregnancy risk assessment are crucial for optimal management and monitoring during pregnancy.
Area of Science:
- Cardiology
- Genetics
- Reproductive Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary genetic heart condition with significant heterogeneity.
- Increasingly diagnosed in women of reproductive age through advanced screening methods.
Purpose of the Study:
- To evaluate maternal and fetal outcomes in women with HCM during pregnancy.
- To outline recommended clinical management and risk stratification strategies.
Main Methods:
- Review of clinical data and outcomes for pregnant women with HCM.
- Emphasis on echocardiography, genetic screening, and clinical evaluations throughout gestation.
Main Results:
- Maternal and fetal outcomes for women with HCM are generally favorable.
- Most women experience moderate morbidity, requiring trimester evaluations and vaginal delivery.
- Symptomatic women or those with significant left ventricular outflow obstruction/arrhythmias face higher risks.
Conclusions:
- Pre-pregnancy evaluation and risk assessment are essential for managing HCM in pregnancy.
- Regular monitoring, including echocardiography, is vital, with more frequent assessments for high-risk individuals.
- Genetic counseling is recommended for women with HCM planning pregnancy.
Abstract:
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac condition and highly heterogeneous. Echocardiography and genetic and clinical screening have led to detection in women of childbearing age. Maternal and fetal outcomes among women with HCM are favorable. Genetic counseling is recommended. Prepregnancy clinical evaluation and risk assessment are paramount in ensuring optimal outcomes. Most women carry moderate risk of morbidity, have clinical evaluations and echocardiography each trimester, and deliver vaginally. Those who are symptomatic or have significant left ventricular outflow obstruction or recurrent arrhythmias prior to pregnancy are at higher risk and should be monitored at least monthly.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mitral Valve Prolapse III: Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Heart Failure II: Pathophysiology

